



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/012003
		Serial No.	09/905,592
		Applicant	Keiya Ozawa et al.
		Filing Date	July 13, 2001
		Group	1636
		IDS Filed	February 19, 2004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

Duplicate over IDS 2/22/04	Anderson, "Human Gene Therapy" <i>Nature</i> 392(Supp.):25-30 (1998).
	Chen, "Cancer Fears Cast Doubts on Future of Gene Therapy" <i>Nature</i> 421:678 (2003).
	Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" <i>Journal of Hepatology</i> 39:731-737 (2003).
	Juergens, "What Next for Human Gene Therapy" <i>BMJ</i> 326:1410-1411 (2003).
	Kakuta et al., "Inhibition of B16 Melanoma Experimental Metastasis by Interferon- γ through Direct Inhibition of Cell Proliferation and Activation of Antitumor Host Mechanisms," <i>Immunology</i> 105:92-100 (2002).
	Kruse "Gene Therapy" <i>American Scientist</i> 87:240-247 (1999).
	Marinkowska and Wiedlocha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," <i>Acta Biochimica Polonica</i> 49(3):735-745 (2002).
	Manuyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoietin Receptor," <i>The Journal of Biological Chemistry</i> , 269(8):5976-5980 (1994).
	O'Farrell et al., "IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways," <i>The EMBO Journal</i> 17(4):1006-1018 (1998).
	Verma and Somia, "Gene Therapy: Promises, Problems and Prospects," <i>Nature</i> 389:239-242 (1997).
Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dimerization Is Ligand-Dependent <i>In Vivo</i> ," <i>The Journal of Biological Chemistry</i> , 270(40):23322-23329 (1995).	
Wimmel et al., "Autocrine Growth Inhibition by Transforming Growth Factor β -1 (TGF β -1) in Human Neuroendocrine Tumor Cells," <i>Gut</i> 52:1308-1316 (2003).	

EXAMINER


DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.		50026/012003	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No.		09/905,592	
				Applicant		Keiya Ozawa et al.	
				Filing Date		July 13, 2001	
				Group		1636	
(37 C.F.R. §1.98(b))				IDS Filed		April 16, 2004	
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
	WO 93/40461	May 27, 1993	WIPO				
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
<i>Duplicate over JAS 4/20/04</i>	Gearing et al., "The IL-6 Signal Transducer gp130: An Oncostatin M Receptor and Affinity Converter for the LIF Receptor," <i>Science</i> 255(5050):1434-1437 (1992).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/012003
		Serial No.	09/905,592
		Applicant	Kei-ya Ozawa et al.
		Filing Date	July 13, 2001
		Group	1636
		IDS Filed	May 26, 2004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)


<i>M</i>	Alexander et al., "Point Mutations within a Dimer Interface Homology Domain of c-Mpl Induce Constitutive Receptor Activity and Tumorigenicity," <i>The EMBO Journal</i> 14(22):5569-5578 (1995).
	Bazan, "Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily," <i>Proc. Natl. Acad. Sci. USA</i> 87:6934-6938 (1990).
	Heldin, "Dimerization of Cell Surface Receptors in Signal Transduction," <i>Cell</i> 80:213-223 (1995).
	Ihle, "Cytokine Receptor Signalling," <i>Nature</i> 377:591-594 (1995).
	Murakami et al., "Critical Cytoplasmic Region of the Interleukin 6 Signal Transducer gp130 Is Conserved in the Cytokine Receptor Family," <i>Proc. Natl. Acad. Sci. USA</i> 88:11349-11353 (1991).
	Ozawa et al., US 2002/0004582 A1, published January 10, 2002.
	Ozawa et al., US 2003/0166161 A1, published September 04, 2003.
	Omura et al., "Acceleration of Granulocyte Colony-Stimulating Factor-Induced Neutrophilic Nuclear Lobulation by Overexpression of Lyn Tyrosine Kinase," <i>Eur. J. Biochem.</i> 269:381-389 (2002).
<i>M</i>	Thornton, "Evolution of Vertebrate Steroid Receptors from an Ancestral Estrogen Receptor by Ligand Exploitation and Serial Genome Expansions," <i>Proc. Natl. Acad. Sci. USA</i> 98(10):5671-5676 (2001).
EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>4/25/05</i>

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



Sheet 1 of 1


SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/012003				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 09/905,592				
		Applicant Keiya Ozawa et al.				
		Filing Date July 13, 2001				
		Group 1655				
(37 C.F.R. §1.98(b))		IDS Filed September 19, 2002				
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
M	Chan et al., "A Murine Cytokine Fusion Toxin Specifically Targeting the Murine Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Receptor on Normal Committed Bone Marrow Progenitor Cells and GM-CSF-Dependent Tumor Cells," <i>Blood</i> 86:2732-2740 (1995).					
	Ito et al., "G-CSFR-Estrogen-R Fusion cDNA as a Novel Selective Amplifier Gene for Controllable Expansion of Transduced Hematopoietic Stem Cells," (Abstract 538) <i>Blood</i> 88:137A (1996).					
	Jackson et al., "Hormone-Conditional Transformation by Fusion Proteins of c-Abl and its Transforming Variants," <i>EMBO J</i> 12:2809-2819 (1993).					
	Nagata and Fukunaga, "Granulocyte Colony-Stimulating Factor and its Receptor," <i>Prog. Growth Factor Res.</i> , 3:131-141 (1991).					
	Ozawa et al., "Development of a Novel Selective Amplifier Gene for <i>In Vivo</i> Selective Expansion of Transduced Hematopoietic Stem Cells," (Abstract 161) <i>Experimental Hematology</i> 24:1053 (1996).					
M	Williams and Park, "Hematopoietic Effects of a Granulocyte-Macrophage Colony-Stimulating Factor/Interleukin-3 Fusion Protein," <i>Cancer</i> 67(Supplement):2705-2707 (1991).					
EXAMINER			DATE CONSIDERED 4/20/05			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



RECEIVED

FEB 27 2004

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/012003		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		(37 C.F.R. § 1.98(b))		Serial No. 09/905,592		
				Applicant Keiya Ozawa et al.		
				Filing Date July 13, 2001		
				Group 1636		
				IDS Filed February 19, 2004		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
M	Anderson, "Human Gene Therapy" <i>Nature</i> 392(Supp.):25-30 (1998).					
	Check, "Cancer Fears Cast Doubts on Future of Gene Therapy" <i>Nature</i> 421:678 (2003).					
	Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" <i>Journal of Hepatology</i> 39:731-737 (2003).					
	Juengst, "What Next for Human Gene Therapy" <i>BMJ</i> 326:1410-1411 (2003).					
	Kakuta et al., "Inhibition of B16 Melanoma Experimental Metastasis by Interferon- γ through Direct Inhibition of Cell Proliferation and Activation of Antitumour Host Mechanisms," <i>Immunology</i> 105:92-100 (2002).					
	Kmiec "Gene Therapy" <i>American Scientist</i> 87:240-247 (1999).					
	Marcinkowska and Więdołcha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," <i>Acta Biochimica Polonica</i> 49(3):735-745 (2002).					
	Maruyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoietin Receptor," <i>The Journal of Biological Chemistry</i> , 269(8):5976-5980 (1994).					
	O'Farrell et al., "IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways," <i>The EMBO Journal</i> 17(4):1006-1018 (1998).					
	Verma and Somia, "Gene Therapy-Promises, Problems and Prospects," <i>Nature</i> 389:239-242 (1997).					
	Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dimerization Is Ligand-Dependent in Vivo," <i>The Journal of Biological Chemistry</i> , 270(40):23322-23329 (1995).					
M	Wimmel et al., "Autocrine Growth Inhibition by Transforming Growth Factor β -1 (TGF β -1) in Human Neuroendocrine Tumour Cells," <i>Gut</i> 52:1308-1316 (2003).					
EXAMINER 						
DATE CONSIDERED				4/25/05		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

[illegible]

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/012003		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Serial No.		09/905,592		
		Applicant		Ozawa et al.		
		Filing Date		July 13, 2001		
		Group		1636		
		IDS Filed		February 24, 2005		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
M	JP 8-504320A	14 May 1996	Japan			Yes
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
EXAMINER				DATE CONSIDERED 4/25/05		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/012003		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		(37 C.F.R. § 1.98(b))		Serial No. 09/905,592		
				Applicant Ozawa et al.		
				Filing Date July 13, 2001		
				Group 1636		
				IDS Filed October 20, 2004		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
M	Baumann et al., "Signaling by the Cytoplasmic Domain of Hematopoietin Receptors Involves Two Distinguishable Mechanisms in Hepatic Cells," <i>J Biol Chem.</i> 269(23):16297-16304 (1994).					
I	Skoda et al., "Murine <i>c-mpl</i> : a Member of the Hematopoietic Growth Factor Receptor Superfamily that Transduces a Proliferative Signal," <i>EMBO J.</i> 12(7):2645-2653 (1993).					
h	Vigon et al., "Characterization of the Murine <i>Mpl</i> Proto-Oncogene, a Member of the Hematopoietic Cytokine Receptor Family: Molecular Cloning, Chromosomal Location and Evidence for a Function in Cell Growth," <i>Oncogene</i> 8(10):2607-2615 (1993).					
EXAMINER				DATE CONSIDERED 4/20/05		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						